Evidence map›Paper›PMID 23201027›Full record

ArticleExperimental eye research2013

Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells.

Juanita Dortch-Carnes, Gianluca Tosini

Abstract read
In one paragraph

Article in Experimental eye research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 27 citations in OpenAlex.

  1. Cardiorespiratory function associated with dietary nitrate supplementation.Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme · 2014
    Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Evidence for the Benefits of Melatonin in Cardiovascular Disease.Frontiers in cardiovascular medicine · 2022
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Juanita Dortch-CarnesDepartment of Pharmacology and Toxicology Morehouse School of Medicine, 720 Westview Drive, SW, Atlanta, GA 30310-1495, USA. jcarnes@msm.edu
Gianluca Tosini
Morehouse School of Medicine · US

Funding

Morehouse School of Medicine Center of Excellence Research Endowment ProgramS21MD000101 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI MONTGOMERY-RICE, VALERIE C. · 2001 to 2015
$74.3M
TRANSCRIPTION FACTORS AND PROSTATE CANCERG12RR003034 · NCRR · MOREHOUSE SCHOOL OF MEDICINE · PI ZHAO, XUEYING · 1986 to 2011
$32.4M
Photic and Circadian Regulation of Retinal MelatoninR01EY022216 · NEI · MOREHOUSE SCHOOL OF MEDICINE · PI TOSINI, GIANLUCA · 2012 to 2015
$1.4M
Circadian Regulation of the PER2::LUC Bioluminescence Rhythm in the Mouse RPER21EY020821 · NEI · MOREHOUSE SCHOOL OF MEDICINE · PI TOSINI, GIANLUCA · 2010 to 2011
$382k
NCRR NIH HHS G12 RR003034NCRR NIH HHS RR003034NEI NIH HHS EY020821NEI NIH HHS EY022216NEI NIH HHS R01 EY022216NEI NIH HHS R21 EY020821NIMHD NIH HHS S21 MD000101
6 · The paper itself

Abstract

The present study was designed to determine the effects of melatonin and its receptor agonists on SNP-released nitric oxide (NO) and cGMP production in aqueous humor producing cells of the ciliary body because these effects may play a role in melatonin receptor-mediated regulation of intraocular pressure (IOP). NO release protocols were carried out using human non-pigmented ciliary epithelial (hNPCE) cells treated in dye free DMEM containing l-arginine (10(-3) M). The cGMP experimental protocols were performed using dye free DMEM containing 3-isobutyl-1-methylxanthine (IBMX, 10(-4) M). The effects of varying concentrations (10(-13), 10(-11), 10(-9), 10(-7), and 10(-5) M) of melatonin, 5-MCA-NAT (putative MT(3) agonist), N-butanoyl-2-(2-methoxy-6H-isoindolo[2, 1-a]indol-11-yl)ethanamine (IIK7; selective MT(2) agonist) or S-27633-1 (selective MT(1) agonist) on sodium nitroprusside (SNP)-released NO or cGMP production were determined in separate experiments. NO and cGMP levels were measured using a colorimetric assay or enzyme immunoassay (EIA), respectively. Melatonin receptor selectivity was evaluated using luzindole (LUZ; nonselective MT(1)/MT(2) antagonist) or 4-phenyl-2-propionamidotetralin (4P-PDOT; selective MT(2) antagonist). Melatonin, 5-MCA-NAT, and IIK7 all caused concentration-dependent reduction of SNP-released NO and cGMP production. The inhibitory actions of melatonin, 5-MCA-NAT and IIK7 were either completely blocked at 10(-13), 10(-11), and 10(-9) M concentrations of the agonists or partially at 10(-7) and 10(-5) M in the presence of luzindole or 4P-PDOT. Results from this study suggest that melatonin and its analogs, 5-MCA-NAT and IIK7 inhibit SNP-released NO and cGMP production via activation of MT(2) receptors in human NPCE cells. These actions may play a role in melatonin agonist-induced regulation of aqueous humor secretion and IOP.

Indexed as

Aqueous HumorCells, CulturedCiliary BodyColorimetryCyclic GMPEpithelial CellsHumansImmunoassayIntraocular PressureIsoindolesMelatoninNitric OxideNitroprussideReceptor, Melatonin, MT1Receptor, Melatonin, MT2Receptors, Melatonin5-methoxycarbonylamino-N-acetyltryptamineCyclic GMPIIK7IsoindolesMelatoninNitric OxideNitroprussideReceptor, Melatonin, MT1Receptor, Melatonin, MT2Receptors, MelatoninTryptamines

Identifiers

PMID23201027
PMCPMC3556185
OpenAlexW2017827574

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.